𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Thalidomide as anti-inflammatory therapy for multiple myeloma

✍ Scribed by Mehta, P; Hussein, M

Book ID
110055648
Publisher
Nature Publishing Group
Year
2003
Tongue
English
Weight
70 KB
Volume
17
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thalidomide–dexamethasone as primary the
Thalidomide–dexamethasone as primary therapy for advanced multiple myeloma
✍ Michael Wang; Donna M. Weber; Kay Delasalle; Raymond Alexanian 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 1 views

## Abstract The value of thalidomide–dexamethasone was assessed in 26 consecutive, previously untreated patients with multiple myeloma of high tumor mass. All showed Hgb < 8.5 g/dL, serum calcium > 11.5 mg/dL, or both. The response rate was 73%, frequency of early death < 3 months was 5%, projected

Bortezomib, thalidomide, and dexamethaso
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma : A retrospective study
✍ Jonathan L. Kaufman; Ajay Nooka; Mark Vrana; Charise Gleason; L. Thompson Heffne 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract ## BACKGROUND: This single‐center retrospective study determined the efficacy of bortezomib, thalidomide, and dexamethasone (BTD) as induction for patients with multiple myeloma (MM) who were eligible for autologous stem cell transplantation (ASCT). ## METHODS: Patients with symptoma